Compare APA & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APA | RDY |
|---|---|---|
| Founded | 1954 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 11.9B |
| IPO Year | 2021 | 2001 |
| Metric | APA | RDY |
|---|---|---|
| Price | $32.97 | $14.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 23 | 1 |
| Target Price | ★ $31.96 | $16.90 |
| AVG Volume (30 Days) | ★ 5.4M | 2.1M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.48% | 0.52% |
| EPS Growth | ★ 75.77 | N/A |
| EPS | ★ 1.26 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.86 | $7.72 |
| Revenue Next Year | N/A | $3.50 |
| P/E Ratio | $26.18 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.87 | $12.19 |
| 52 Week High | $45.66 | $15.67 |
| Indicator | APA | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 36.05 | 65.97 |
| Support Level | $22.73 | $13.80 |
| Resistance Level | $38.75 | $14.87 |
| Average True Range (ATR) | 1.06 | 0.31 |
| MACD | -0.24 | 0.21 |
| Stochastic Oscillator | 6.68 | 67.76 |
APA Corp is an independent exploration and production company. It develops and produces crude oil, natural gas, and natural gas liquids. The company's business has oil and gas operations in four segments: Egypt, the North Sea, Suriname, and the U.S. The company generates the majority of its revenue from the U.S. reporting segment. The company also has exploration interests in Uruguay, Alaska, and other international locations.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.